PL356237A1 - Pochodne pirymidyny jako selektywne inhibitory COX-2 - Google Patents

Pochodne pirymidyny jako selektywne inhibitory COX-2

Info

Publication number: PL356237A1
Authority: PL; Poland
Prior art keywords: cox; selective inhibitors; pyrimidine derivatives; 6alkyl; compounds
Prior art date: 1999-11-26

Application number

PL00356237A

Other languages

English (en)

Inventor

Richard Howard Green

Charles David Hartley

Alan Naylor

Jeremy John Payne

Neil Anthony Pegg

Original Assignee

Glaxo Group Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-11-26

Filing date

2000-11-23

Publication date

2004-06-28

2000-11-23 Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited

2004-06-28 Publication of PL356237A1 publication Critical patent/PL356237A1/pl

Links

229940124639 Selective inhibitor Drugs 0.000 title abstract 2
101150071146 COX2 gene Proteins 0.000 title 1
101100114534 Caenorhabditis elegans ctc-2 gene Proteins 0.000 title 1
101150000187 PTGS2 gene Proteins 0.000 title 1
229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 title 1
150000003230 pyrimidines Chemical class 0.000 title 1
125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 2
125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
206010061218 Inflammation Diseases 0.000 abstract 1
208000002193 Pain Diseases 0.000 abstract 1
102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 abstract 1
108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 abstract 1
206010037660 Pyrexia Diseases 0.000 abstract 1
150000001924 cycloalkanes Chemical class 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
230000004054 inflammatory process Effects 0.000 abstract 1
230000003389 potentiating effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Virology (AREA)
Diabetes (AREA)
Pain & Pain Management (AREA)
Endocrinology (AREA)
Physical Education & Sports Medicine (AREA)
Oncology (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Communicable Diseases (AREA)
Reproductive Health (AREA)
Cardiology (AREA)
Molecular Biology (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Obesity (AREA)
Pregnancy & Childbirth (AREA)
Urology & Nephrology (AREA)
Pulmonology (AREA)
Gynecology & Obstetrics (AREA)
AIDS & HIV (AREA)
Hospice & Palliative Care (AREA)

PL00356237A 1999-11-26 2000-11-23 Pochodne pirymidyny jako selektywne inhibitory COX-2 PL356237A1 (pl)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB9927844.2A GB9927844D0 (en)	1999-11-26	1999-11-26	Chemical compounds

Publications (1)

Publication Number	Publication Date
PL356237A1 true PL356237A1 (pl)	2004-06-28

Family

ID=10865107

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL00356237A PL356237A1 (pl)	1999-11-26	2000-11-23	Pochodne pirymidyny jako selektywne inhibitory COX-2

Country Status (21)

Country	Link
US (1)	US6780869B1 (pl)
EP (1)	EP1235812B1 (pl)
JP (1)	JP2003514898A (pl)
KR (1)	KR20020063899A (pl)
CN (1)	CN1399633A (pl)
AT (1)	ATE316962T1 (pl)
AU (1)	AU2508401A (pl)
BR (1)	BR0015821A (pl)
CA (1)	CA2395049A1 (pl)
CO (1)	CO5271666A1 (pl)
CZ (1)	CZ20021802A3 (pl)
DE (1)	DE60025848T2 (pl)
ES (1)	ES2256086T3 (pl)
GB (1)	GB9927844D0 (pl)
HU (1)	HUP0203385A3 (pl)
IL (1)	IL149586A0 (pl)
MX (1)	MXPA02005231A (pl)
NO (1)	NO20022470L (pl)
PE (1)	PE20011008A1 (pl)
PL (1)	PL356237A1 (pl)
WO (1)	WO2001038311A2 (pl)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9927844D0 (en)	1999-11-26	2000-01-26	Glaxo Group Ltd	Chemical compounds
GB0003224D0 (en)	2000-02-11	2000-04-05	Glaxo Group Ltd	Chemical compounds
GB0021494D0 (en) *	2000-09-01	2000-10-18	Glaxo Group Ltd	Chemical comkpounds
GB0112803D0 (en) *	2001-05-25	2001-07-18	Glaxo Group Ltd	Pyrimidine derivatives
GB0112810D0 (en) *	2001-05-25	2001-07-18	Glaxo Group Ltd	Pyrimidine derivatives
GB0112802D0 (en) *	2001-05-25	2001-07-18	Glaxo Group Ltd	Pyrimidine derivatives
GB0119477D0 (en) *	2001-08-09	2001-10-03	Glaxo Group Ltd	Pyrimidine derivatives
WO2003033447A1 (en)	2001-10-10	2003-04-24	Hitachi High-Technologies Corporation	Luminous compounds and labeling reagents using the same
RU2286151C2 (ru) *	2002-02-22	2006-10-27	Уорнер-Ламберт Компани Ллс	Комбинации альфа-2-дельта-лиганда с селективным ингибитором циклооксигеназы-2
DE60305053T2 (de) *	2002-08-19	2006-08-31	Glaxo Group Ltd., Greenford	Pyrimidinderivate als selektive cox-2-inhibitoren
UY27939A1 (es) *	2002-08-21	2004-03-31	Glaxo Group Ltd	Compuestos
GB0221443D0 (en) *	2002-09-16	2002-10-23	Glaxo Group Ltd	Pyridine derivates
GB0227443D0 (en) *	2002-11-25	2002-12-31	Glaxo Group Ltd	Pyrimidine derivatives
WO2005000227A2 (en) *	2003-06-06	2005-01-06	Intermune, Inc.	Methods of treating tnf-mediated disorders
GB0319037D0 (en) *	2003-08-13	2003-09-17	Glaxo Group Ltd	7-Azaindole Derivatives
GB0813142D0 (en)	2008-07-17	2008-08-27	Glaxo Group Ltd	Novel compounds
PE20120325A1 (es) *	2009-05-19	2012-04-12	Dow Agrosciences Llc	Aminopirimidinas sustituidas con arilo como agentes fungicidas
AR081331A1 (es)	2010-04-23	2012-08-08	Cytokinetics Inc	Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
AR081626A1 (es)	2010-04-23	2012-10-10	Cytokinetics Inc	Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
EP2560488B1 (en)	2010-04-23	2015-10-28	Cytokinetics, Inc.	Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
ES2529233T3 (es)	2010-07-09	2015-02-18	Convergence Pharmaceuticals Limited	Compuestos tetrazol como bloqueadores de canales de calcio
DK3261640T3 (da)	2015-02-25	2022-07-11	Univ California	5ht-agonister til behandling af epilepsilidelser

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6020343A (en)	1995-10-13	2000-02-01	Merck Frosst Canada, Inc.	(Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors
SI0912518T1 (en)	1996-07-18	2003-12-31	Merck Frosst Canada & Co.	Substituted pyridines as selective cyclooxygenase-2 inhibitors
JP2002514195A (ja)	1996-12-05	2002-05-14	アムジエン・インコーポレーテツド	置換ピリミジン化合物およびそれの使用
GB9927844D0 (en)	1999-11-26	2000-01-26	Glaxo Group Ltd	Chemical compounds
GB0003224D0 (en)	2000-02-11	2000-04-05	Glaxo Group Ltd	Chemical compounds

1999
- 1999-11-26 GB GBGB9927844.2A patent/GB9927844D0/en not_active Ceased
2000
- 2000-11-23 WO PCT/EP2000/011673 patent/WO2001038311A2/en not_active Ceased
- 2000-11-23 DE DE60025848T patent/DE60025848T2/de not_active Expired - Fee Related
- 2000-11-23 EP EP00988751A patent/EP1235812B1/en not_active Expired - Lifetime
- 2000-11-23 BR BR0015821-6A patent/BR0015821A/pt not_active Application Discontinuation
- 2000-11-23 CN CN00816293A patent/CN1399633A/zh active Pending
- 2000-11-23 AT AT00988751T patent/ATE316962T1/de not_active IP Right Cessation
- 2000-11-23 PE PE2000001249A patent/PE20011008A1/es not_active Application Discontinuation
- 2000-11-23 HU HU0203385A patent/HUP0203385A3/hu unknown
- 2000-11-23 MX MXPA02005231A patent/MXPA02005231A/es unknown
- 2000-11-23 CA CA002395049A patent/CA2395049A1/en not_active Abandoned
- 2000-11-23 KR KR1020027006732A patent/KR20020063899A/ko not_active Withdrawn
- 2000-11-23 US US10/130,516 patent/US6780869B1/en not_active Expired - Fee Related
- 2000-11-23 CZ CZ20021802A patent/CZ20021802A3/cs unknown
- 2000-11-23 ES ES00988751T patent/ES2256086T3/es not_active Expired - Lifetime
- 2000-11-23 IL IL14958600A patent/IL149586A0/xx unknown
- 2000-11-23 JP JP2001540074A patent/JP2003514898A/ja active Pending
- 2000-11-23 PL PL00356237A patent/PL356237A1/pl not_active Application Discontinuation
- 2000-11-23 AU AU25084/01A patent/AU2508401A/en not_active Abandoned
- 2000-11-24 CO CO00090138A patent/CO5271666A1/es not_active Application Discontinuation
2002
- 2002-05-24 NO NO20022470A patent/NO20022470L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
CZ20021802A3 (cs)	2002-10-16
HUP0203385A2 (en)	2003-05-28
NO20022470L (no)	2002-07-18
KR20020063899A (ko)	2002-08-05
ATE316962T1 (de)	2006-02-15
WO2001038311A2 (en)	2001-05-31
ES2256086T3 (es)	2006-07-16
BR0015821A (pt)	2002-07-30
CA2395049A1 (en)	2001-05-31
NO20022470D0 (no)	2002-05-24
DE60025848T2 (de)	2006-08-03
MXPA02005231A (es)	2002-11-07
EP1235812A2 (en)	2002-09-04
CO5271666A1 (es)	2003-04-30
WO2001038311A3 (en)	2001-11-01
CN1399633A (zh)	2003-02-26
GB9927844D0 (en)	2000-01-26
PE20011008A1 (es)	2001-10-15
EP1235812B1 (en)	2006-02-01
US6780869B1 (en)	2004-08-24
JP2003514898A (ja)	2003-04-22
AU2508401A (en)	2001-06-04
IL149586A0 (en)	2002-11-10
DE60025848D1 (en)	2006-04-13
HUP0203385A3 (en)	2003-07-28

Legal Events

Date	Code	Title	Description
2009-04-30	REFS	Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)

Publication	Publication Date	Title
IL149586A0 (en)	2002-11-10	Pyrimidine derivatives as selective inhibitors of cox-2
MY119689A (en)	2005-06-30	Pyrazolopyridine derivatives
AU2661400A (en)	2000-09-21	Pyrazolopyridines
JO2311B1 (en)	2005-09-12	Alkyl inhibitors Ariel phosphodiesterase-4
GB0005251D0 (en)	2000-04-26	Therapeutic compounds
EE200100558A (et)	2002-12-16	Triarüülhappe derivaat, seda sisaldav farmatseutiline kompositsioon ja ühendi raviotstarbeline kasutamine
TR200200579T2 (tr)	2002-12-23	Amino-tirazolpiridin türevleri.
BG106586A (en)	2003-01-31	Pyrazolopyramidines as therapeutic agents
MY138352A (en)	2009-05-29	Benzothiazole derivatives
AU2003225617A1 (en)	2003-09-16	Thiadiazolylpiperazine derivatives useful for treating or preventing pain
CO5271691A1 (es)	2003-04-30	Nuevos compuestos
MY126917A (en)	2006-10-31	Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors
EA200500377A1 (ru)	2005-08-25	Пиразольные производные как ингибиторы трансформирующего фактора роста (tgf)
YU87202A (sh)	2006-05-25	Derivati arilmetilamina koji se koriste kao inhibitori triptaze
CA2238875A1 (en)	1997-06-26	Tri-aryl ethane derivatives as pde iv inhibitors
SE9903997D0 (sv)	1999-11-03	New compounds
AU2003250471A8 (en)	2004-02-25	Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors
DE50211929D1 (en)	2008-04-30	Pyrimidinderivate
DE60035429D1 (de)	2007-08-16	Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
AU2001290480A1 (en)	2002-04-08	Cyclized benzamide neurokinin antagonists for use in therapy
CA2412596A1 (en)	2002-01-03	Cyclic gmp-specific phosphodiesterase inhibitors
SE9803773D0 (sv)	1998-11-05	Compounds
AU2002359150A8 (en)	2003-06-30	Therapeutic heterocycles
MXPA04005809A (es)	2004-09-13	Inhibidores de proteinas quinasas.
ATE330958T1 (de)	2006-07-15	Pyrazino 1'2':1,6öpyrido 3,4-böindolderivate